Omnicell (NASDAQ: OMCL) and NantHealth (NASDAQ:NH) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Volatility & Risk

Omnicell has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, NantHealth has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500.

Insider & Institutional Ownership

99.9% of Omnicell shares are held by institutional investors. Comparatively, 6.9% of NantHealth shares are held by institutional investors. 3.8% of Omnicell shares are held by company insiders. Comparatively, 58.0% of NantHealth shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Omnicell and NantHealth’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Omnicell 2.88% 1.54% 0.77%
NantHealth -225.76% -46.09% -25.23%

Valuation and Earnings

This table compares Omnicell and NantHealth’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Omnicell $716.16 million 2.22 $20.60 million $0.51 82.35
NantHealth $100.38 million 3.19 -$184.10 million ($1.78) -1.66

Omnicell has higher revenue and earnings than NantHealth. NantHealth is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Omnicell and NantHealth, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omnicell 0 2 5 0 2.71
NantHealth 0 0 4 0 3.00

Omnicell currently has a consensus price target of $56.14, suggesting a potential upside of 33.67%. NantHealth has a consensus price target of $9.00, suggesting a potential upside of 204.05%. Given NantHealth’s stronger consensus rating and higher probable upside, analysts plainly believe NantHealth is more favorable than Omnicell.

Summary

Omnicell beats NantHealth on 9 of the 13 factors compared between the two stocks.

Omnicell Company Profile

Omnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software. The Medication Adherence segment includes the development, manufacturing and selling of consumable medication blister cards, packaging equipment, medication synchronization platform, and ancillary products and services. Its products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS, Surgichem, SureMed and the Omnicell brand.

NantHealth Company Profile

NantHealth, Inc. is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. The Company also offers Nant Operating System (NantOS) and NantOS applications to healthcare providers and payors, self-insured employers and biopharmaceutical companies. It offers CLINICS, an integrated solution that includes GPS Cancer, NantOS and the NantOS applications. The CLINICS solution includes System Infrastructure, Knowledge Platform, Provider Platform and Payor Platform.

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.